Jan 16 2017
A January, 2017 publication indicates that apixaban (Eliquis) yields fewer bleeds, less kidney damage, and fewer strokes in patients with atrial fibrillation after transfemoral aortic valve replacement (TAVR) over the first 30 days of treatment. See Seeger J, Gonska B, Rodewald C, Rottbauer W, Wöhrle J. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement (TAVR). JACC: Cardiovascular Interventions 2017;10: DOI: 10.1016/j.jcin.2016.10.023.
Comments (0)
Anticoagulant Therapy
No comments here.